Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free PETS Stock Alerts

PetMed Express (PETS) Financials

PetMed Express logo
$1.97 -0.03 (-1.50%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$1.97 0.00 (0.00%)
As of 07/17/2026 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for PetMed Express

Annual Income Statements for PetMed Express

This table shows PetMed Express' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 21 24 37 38 26 24 19 5.14 -7.46 -6.27 -57
Consolidated Net Income / (Loss)		 21 24 37 38 26 24 19 5.14 -7.46 -6.27 -57
Net Income / (Loss) Continuing Operations		 21 24 37 38 26 24 19 5.14 -7.46 -6.27 -57
Total Pre-Tax Income 		33 38 54 49 34 31 24 7.45 -6.27 -0.59 -57
Total Operating Income		 32 37 52 46 31 31 24 6.05 -8.16 -1.53 -59
Total Gross Profit		 76 79 98 95 81 84 77 77 85 69 50
Total Revenue		 235 249 274 283 284 304 272 248 274 227 179
Operating Revenue		 235 249 274 283 284 304 272 248 274 227 179
Total Cost of Revenue		 158 170 176 188 203 219 195 171 189 158 129
Operating Cost of Revenue		 158 170 176 188 203 219 195 171 189 158 129
Total Operating Expenses		 44 42 46 49 50 54 53 70 93 71 109
Selling, General & Admin Expense		 21 23 24 25 25 30 31 42 55 39 51
Marketing Expense		 22 18 19 22 23 22 19 25 31 24 22
Depreciation Expense		 0.77 1.37 2.13 2.23 2.26 2.43 2.74 3.55 7.06 7.04 9.39
Impairment Charge		 - - - - - - - 0.00 0.00 1.20 27
Total Other Income / (Expense), net		 0.18 0.44 1.65 2.95 2.92 0.42 -0.11 1.39 1.89 0.94 1.31
Interest & Investment Income		 0.19 0.14 0.66 1.86 1.75 - - 0.45 0.51 0.19 0.51
Other Income / (Expense), net		 -0.01 0.30 1.00 1.08 1.17 1.32 1.03 0.94 1.38 0.76 0.80
Income Tax Expense		 12 14 17 11 8.04 7.03 5.47 2.31 1.19 5.68 -0.07
Basic Earnings per Share		 $1.02 $1.18 $1.83 $1.84 $1.29 $1.19 $0.93 $0.25 ($0.37) ($0.30) ($2.74)
Weighted Average Basic Shares Outstanding		 20.12M 20.23M 20.35M 20.46M 20.04M 20.06M 20.18M 20.27M 20.40M 20.60M 20.92M
Diluted Earnings per Share		 $1.02 $1.17 $1.82 $1.84 $1.29 $1.19 $0.92 $0.25 ($0.37) ($0.30) ($2.74)
Weighted Average Diluted Shares Outstanding		 20.25M 20.38M 20.43M 20.49M 20.06M 20.12M 20.36M 20.34M 20.40M 20.60M 20.92M
Weighted Average Basic & Diluted Shares Outstanding		 20.20M 20.53M 20.40M 20.50M 20.17M 20.27M 20.99M 21.17M 20.61M - 21.37M
Cash Dividends to Common per Share		 $0.72 $0.76 $0.85 $1.06 $1.08 $1.12 $1.20 $1.20 $0.60 $0.00 $0.00

Quarterly Income Statements for PetMed Express

This table shows PetMed Express' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.72 -2.03 -5.02 3.75 2.33 -0.71 -12 -34 -8.52 -11 -4.06
Consolidated Net Income / (Loss)		 0.72 -2.03 -5.02 3.75 2.33 -0.71 -12 -34 -8.52 -11 -4.06
Net Income / (Loss) Continuing Operations		 0.72 -2.03 -5.02 3.75 2.33 -0.71 -12 -34 -8.52 -11 -4.06
Total Pre-Tax Income 		1.28 -2.65 -3.48 4.71 0.93 -0.24 -5.98 -34 -8.51 -11 -4.16
Total Operating Income		 0.88 -3.07 -3.84 4.39 0.55 -0.45 -6.02 -34 -8.38 -10 -5.69
Total Gross Profit		 20 18 18 19 19 16 15 14 12 9.46 14
Total Revenue		 71 65 67 66 58 52 51 51 44 41 43
Operating Revenue		 71 65 67 66 58 52 51 51 44 41 43
Total Cost of Revenue		 51 47 48 47 39 36 36 37 32 31 29
Operating Cost of Revenue		 51 47 48 47 39 36 36 37 32 31 29
Total Operating Expenses		 19 21 22 15 18 17 21 49 21 20 20
Selling, General & Admin Expense		 12 13 14 4.87 10 11 12 13 14 12 11
Marketing Expense		 5.51 5.76 5.97 8.06 6.07 4.21 5.45 6.05 4.34 5.33 5.79
Depreciation Expense		 1.71 1.77 1.90 1.72 1.66 1.59 2.07 2.28 2.28 2.40 2.43
Total Other Income / (Expense), net		 0.41 0.43 0.36 0.33 0.37 0.21 0.04 -0.01 -0.13 -0.07 1.53
Interest & Investment Income		 0.15 0.14 - 0.10 0.19 0.03 -0.12 -0.20 -0.33 -0.22 1.26
Other Income / (Expense), net		 0.25 0.29 0.33 0.23 0.19 0.18 0.16 0.19 0.20 0.15 0.27
Income Tax Expense		 0.57 -0.62 1.54 0.96 -1.40 0.47 5.66 0.01 0.01 0.01 -0.10
Basic Earnings per Share		 $0.04 ($0.10) ($0.25) $0.18 $0.11 ($0.03) ($0.56) ($1.65) ($0.41) ($0.50) ($0.18)
Weighted Average Basic Shares Outstanding		 20.38M 20.43M 20.40M 20.51M 20.60M 20.63M 20.60M 20.76M 20.89M 21.01M 20.92M
Diluted Earnings per Share		 $0.03 ($0.10) ($0.24) $0.18 $0.11 ($0.03) ($0.56) ($1.65) ($0.41) ($0.50) ($0.18)
Weighted Average Diluted Shares Outstanding		 20.78M 20.43M 20.40M 20.94M 20.94M 20.63M 20.60M 20.76M 20.89M 21.01M 20.92M
Weighted Average Basic & Diluted Shares Outstanding		 21.15M - 20.61M 20.60M 20.66M 20.66M 0.00 - 21.37M 21.40M 21.37M

Annual Cash Flow Statements for PetMed Express

This table details how cash moves in and out of PetMed Express' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.03 21 19 23 3.23 15 -7.64 -6.99 -49 -0.58 -33
Net Cash From Operating Activities		 21 47 37 45 39 40 18 28 4.32 4.72 -28
Net Cash From Continuing Operating Activities		 21 47 37 45 39 40 18 28 4.32 4.72 -28
Net Income / (Loss) Continuing Operations		 21 24 37 38 26 24 19 5.14 -7.46 -6.27 -57
Consolidated Net Income / (Loss)		 21 24 37 38 26 24 19 5.14 -7.46 -6.27 -57
Depreciation Expense		 0.77 1.37 2.13 2.23 2.26 2.43 2.74 3.55 7.06 7.04 9.39
Non-Cash Adjustments To Reconcile Net Income		 1.87 2.36 2.69 3.18 3.01 3.44 4.71 6.83 7.98 -4.56 31
Changes in Operating Assets and Liabilities, net		 -2.16 20 -4.72 1.99 7.72 10 -7.67 12 -3.26 8.51 -12
Net Cash From Investing Activities		 -4.49 -11 -0.70 -0.62 -2.31 -2.43 -1.75 -10 -41 -5.11 -4.62
Net Cash From Continuing Investing Activities		 -4.49 -11 -0.70 -0.62 -2.31 -2.43 -1.75 -10 -41 -5.11 -4.62
Purchase of Property, Plant & Equipment		 -20 -11 -0.70 -0.62 -2.31 -2.43 -1.75 -5.26 -4.51 -5.11 -4.62
Acquisitions		 - - - - - - 0.00 0.00 -36 0.00 0.00
Purchase of Investments		 - - - - - 0.00 0.00 -5.00 -0.30 0.00 0.00
Net Cash From Financing Activities		 -15 -16 -17 -22 -33 -23 -24 -25 -12 -0.18 -0.30
Net Cash From Continuing Financing Activities		 -15 -16 -17 -22 -33 -23 -24 -25 -12 -0.18 -0.30
Payment of Dividends		 -15 -16 -17 -22 -22 -23 -24 -25 -12 -0.18 -0.02
Other Financing Activities, net		 0.14 - - - - -0.20 - - 0.00 0.00 -0.28
Cash Income Taxes Paid		 12 11 18 11 7.14 10 6.09 4.31 0.13 0.53 0.05

Quarterly Cash Flow Statements for PetMed Express

This table details how cash moves in and out of PetMed Express' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -8.06 -4.03 5.86 -9.30 6.05 -1.94 4.62 -14 -5.03 -9.18 -5.50
Net Cash From Operating Activities		 -0.78 -2.59 7.13 -8.52 7.39 -1.17 7.01 -12 -2.17 -9.21 -4.74
Net Cash From Continuing Operating Activities		 -0.78 -2.59 7.13 -8.52 7.39 -1.17 7.01 -12 -2.17 -9.21 -4.74
Net Income / (Loss) Continuing Operations		 0.72 -2.03 -5.02 3.75 2.33 -0.71 -12 -34 -8.52 -11 -4.06
Consolidated Net Income / (Loss)		 0.72 -2.03 -5.02 3.75 2.33 -0.71 -12 -34 -8.52 -11 -4.06
Depreciation Expense		 1.71 1.77 1.90 1.72 1.66 1.59 2.07 2.28 2.28 2.40 2.43
Non-Cash Adjustments To Reconcile Net Income		 1.94 1.92 2.14 -7.93 0.72 0.36 1.95 28 0.37 2.48 0.36
Changes in Operating Assets and Liabilities, net		 -5.15 -4.26 8.11 -6.07 2.69 -2.41 15 -8.36 3.70 -3.53 -3.47
Net Cash From Investing Activities		 -0.98 -1.42 -1.25 -0.68 -1.27 -0.78 -2.39 -1.29 -2.62 0.02 -0.72
Net Cash From Continuing Investing Activities		 -0.98 -1.42 -1.25 -0.68 -1.27 -0.78 -2.39 -1.29 -2.62 0.02 -0.72
Purchase of Property, Plant & Equipment		 -0.98 -1.12 -1.25 -0.68 -1.27 -0.78 -2.39 -1.29 -2.62 0.02 -0.72
Net Cash From Financing Activities		 -6.30 -0.02 -0.02 -0.10 -0.07 -0.00 -0.01 -0.03 -0.23 - -0.04
Net Cash From Continuing Financing Activities		 -6.30 -0.02 -0.02 -0.10 -0.07 -0.00 -0.01 -0.03 -0.23 - -0.04
Payment of Dividends		 -6.30 -0.02 -0.02 -0.10 -0.07 -0.00 -0.01 -0.00 -0.02 -0.00 0.00
Other Financing Activities, net		 - - - 0.00 - - - -0.03 -0.21 0.00 -0.04
Cash Income Taxes Paid		 - 0.04 0.09 0.08 0.39 0.01 0.05 -0.00 0.07 0.01 -0.02

Annual Balance Sheets for PetMed Express

This table presents PetMed Express' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 90 113 135 154 155 187 180 167 170 149 81
Total Current Assets		 68 82 105 126 129 161 151 130 94 79 44
Cash & Equivalents		 38 59 78 101 104 119 111 104 55 55 21
Accounts Receivable		 1.72 1.81 2.29 2.54 3.84 2.59 1.91 1.74 3.28 2.32 1.91
Inventories, net		 26 20 23 21 18 34 32 19 29 16 14
Prepaid Expenses		 2.44 1.02 0.88 1.41 3.53 4.50 4.87 4.72 6.33 5.33 6.38
Current Deferred & Refundable Income Taxes		 0.24 0.00 0.79 0.58 0.00 0.96 0.68 0.86 0.19 0.30 0.26
Plant, Property, & Equipment, net		 21 30 29 27 25 25 24 26 27 29 26
Total Noncurrent Assets		 1.72 0.86 0.86 0.86 0.86 0.86 4.24 11 50 41 11
Goodwill		 - - - - - - - 0.00 27 27 0.00
Intangible Assets		 0.86 0.86 0.86 0.86 0.86 0.86 0.86 5.86 17 13 11
Other Noncurrent Operating Assets		 - - - - - - - 0.00 1.43 0.97 0.51
Total Liabilities & Shareholders' Equity		 90 113 135 154 155 187 180 167 170 149 81
Total Liabilities		 7.08 19 19 20 25 46 56 58 73 64 52
Total Current Liabilities		 7.08 18 18 19 24 45 56 58 72 63 52
Accounts Payable		 5.00 15 15 16 20 40 28 25 37 24 21
Accrued Expenses		 2.08 2.48 2.84 2.35 4.21 5.39 4.59 6.19 7.06 12 7.67
Current Deferred Revenue		 - - - - - - - 0.00 2.60 2.09 0.69
Current Deferred & Payable Income Tax Liabilities		 - 0.66 - 0.00 0.47 - - - 0.00 0.08 0.02
Other Taxes Payable		 - - - - - - 24 26 25 25 22
Other Current Liabilities		 - - - - - - - 0.00 0.46 0.46 0.49
Total Noncurrent Liabilities		 0.00 1.09 1.00 1.12 0.97 1.28 0.00 0.00 1.00 0.80 0.22
Noncurrent Deferred & Payable Income Tax Liabilities		 - 1.09 1.00 1.12 0.97 1.28 - - 0.00 0.26 0.18
Other Noncurrent Operating Liabilities		 - - - - - - - 0.00 1.00 0.54 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 83 93 116 135 130 141 123 110 97 85 29
Total Preferred & Common Equity		 83 93 116 135 130 141 123 110 97 85 29
Preferred Stock		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Total Common Equity		 83 93 116 135 130 141 123 110 97 85 29
Common Stock		 4.89 6.83 9.40 12 3.82 7.13 12 18 25 19 20
Retained Earnings		 78 87 106 122 126 134 112 92 72 67 9.26

Quarterly Balance Sheets for PetMed Express

This table presents PetMed Express' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025
Total Assets		 163 173 153 146 145 110 100 88
Total Current Assets		 85 96 78 71 68 68 59 49
Cash & Equivalents		 53 49 46 52 50 41 36 27
Accounts Receivable		 2.17 1.93 2.26 1.62 2.26 1.61 1.97 1.56
Inventories, net		 19 35 26 13 12 18 15 12
Prepaid Expenses		 9.66 8.80 3.85 3.66 3.89 6.50 6.36 7.57
Current Deferred & Refundable Income Taxes		 0.44 0.80 0.00 0.37 0.34 0.30 0.26 0.26
Plant, Property, & Equipment, net		 27 27 26 26 28 29 28 28
Total Noncurrent Assets		 51 51 49 49 48 13 13 12
Goodwill		 27 27 27 27 27 0.00 0.00 0.00
Intangible Assets		 17 17 16 16 15 12 12 11
Other Noncurrent Operating Assets		 1.83 1.63 1.30 1.19 1.08 0.85 0.74 0.63
Total Liabilities & Shareholders' Equity		 163 173 153 146 145 110 100 88
Total Liabilities		 62 73 59 50 49 58 57 55
Total Current Liabilities		 61 72 58 49 48 58 57 55
Accounts Payable		 25 39 24 17 11 20 19 20
Accrued Expenses		 6.70 5.56 5.20 5.41 11 11 11 8.00
Current Deferred Revenue		 3.57 3.07 2.15 1.65 1.16 1.11 1.00 0.83
Current Deferred & Payable Income Tax Liabilities		 - - 0.72 - - 0.10 0.00 0.00
Other Taxes Payable		 25 24 25 24 24 25 25 25
Other Current Liabilities		 0.76 0.75 0.44 0.45 0.45 0.47 0.48 0.49
Total Noncurrent Liabilities		 1.08 0.89 0.88 0.77 0.65 0.68 0.55 0.43
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 0.26 0.26 0.26
Other Noncurrent Operating Liabilities		 1.08 0.89 0.88 0.77 0.65 - - 0.17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 100 100 94 96 96 52 43 33
Total Preferred & Common Equity		 100 100 94 96 96 52 43 33
Preferred Stock		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Total Common Equity		 100 100 94 96 96 52 43 33
Common Stock		 22 23 17 18 18 19 19 19
Retained Earnings		 79 77 77 79 78 32 24 13

Annual Metrics And Ratios for PetMed Express

This table displays calculated financial ratios and metrics derived from PetMed Express' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 20,326,942.00 20,526,108.00 20,601,106.00 20,673,921.00 20,166,382.00 20,271,122.00 20,978,529.00 21,084,277.00 - 20,656,457.00 21,400,495.00
DEI Adjusted Shares Outstanding		 20,326,942.00 20,526,108.00 20,601,106.00 20,673,921.00 20,166,382.00 20,271,122.00 20,978,529.00 21,084,277.00 - 20,656,457.00 21,400,495.00
DEI Earnings Per Adjusted Shares Outstanding		 1.01 1.16 1.81 1.83 1.28 1.18 0.89 0.24 - -0.30 -2.68
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 2.31% 6.18% 9.88% 3.51% 0.25% 6.85% -10.31% -9.08% 9.54% -17.19% -21.13%
EBITDA Growth		 17.23% 18.12% 41.13% -10.45% -30.47% -0.38% -18.15% -62.43% -97.42% 2,204.04% -873.62%
EBIT Growth		 17.25% 16.70% 40.62% -11.06% -31.98% -0.93% -20.50% -72.37% -196.98% 88.62% -7,396.11%
NOPAT Growth		 17.98% 15.10% 53.50% -1.83% -33.40% -0.13% -20.33% -77.78% -236.76% 81.25% -3,734.84%
Net Income Growth		 17.84% 15.81% 56.53% 1.23% -31.50% -7.47% -21.75% -72.54% -245.21% 15.98% -813.51%
EPS Growth		 17.24% 14.71% 55.56% 1.10% -29.89% -7.75% -22.69% -72.83% -248.00% 18.92% -813.33%
Operating Cash Flow Growth		 -34.30% 124.22% -20.81% 20.76% -13.94% 3.17% -53.84% 50.30% -84.47% 9.29% -701.82%
Free Cash Flow Firm Growth		 -102.95% 4,056.41% -4.31% 18.62% -19.40% -13.48% 6.27% -63.20% -486.86% 124.11% -282.76%
Invested Capital Growth		 88.01% -23.97% 9.12% -9.64% -23.14% -14.04% -45.18% -52.47% 604.68% -26.60% -75.25%
Revenue Q/Q Growth		 2.35% 3.16% 1.59% -0.96% 3.54% -2.64% -0.43% -4.43% 1.48% -3.72% -4.25%
EBITDA Q/Q Growth		 2.54% 9.80% 4.69% -11.07% 2.25% -18.36% 21.39% -34.70% -90.60% -25.72% 1.61%
EBIT Q/Q Growth		 2.43% 9.27% 4.84% -11.58% 2.43% -19.12% 22.39% -45.79% -108.10% -148.95% 0.75%
NOPAT Q/Q Growth		 2.38% 9.37% 7.18% -9.81% 2.32% -19.77% 25.44% -55.18% -79.82% -977.10% 0.56%
Net Income Q/Q Growth		 2.32% 9.59% 7.75% -8.63% 1.51% -22.33% 23.44% -43.13% -180.18% -1,856.58% 11.69%
EPS Q/Q Growth		 3.03% 9.35% 7.69% -8.91% 3.20% -23.23% 24.32% -43.18% -164.29% -1,600.00% 12.18%
Operating Cash Flow Q/Q Growth		 -16.29% 57.03% -26.28% 31.76% 11.97% 48.17% -53.84% 3.76% -37.58% -2.34% -70.66%
Free Cash Flow Firm Q/Q Growth		 -103.83% 1,996.07% -28.64% 36.66% 14.88% -16.72% -38.29% 441.69% 0.21% 113.56% -1,600.02%
Invested Capital Q/Q Growth		 151.16% -16.50% 30.40% -13.96% -25.72% -29.47% 0.00% -52.74% -18.15% -34.00% 28.64%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 32.51% 31.83% 35.72% 33.63% 28.60% 27.77% 28.26% 30.90% 27.98% 30.46% 28.05%
EBITDA Margin		 14.12% 15.71% 20.18% 17.46% 12.11% 11.29% 10.30% 4.26% 0.10% 2.76% -27.08%
Operating Margin		 13.80% 15.04% 19.04% 16.29% 10.90% 10.06% 8.92% 2.44% -2.90% -0.67% -32.77%
EBIT Margin		 13.80% 15.16% 19.41% 16.67% 11.31% 10.49% 9.30% 2.83% -2.41% -0.34% -32.33%
Profit (Net Income) Margin		 8.76% 9.56% 13.62% 13.32% 9.10% 7.88% 6.87% 2.08% -2.66% -2.76% -32.00%
Tax Burden Percent		 63.15% 62.81% 69.31% 76.83% 76.27% 77.28% 77.39% 69.04% 118.99% 1,068.31% 99.87%
Interest Burden Percent		 100.59% 100.37% 101.24% 103.94% 105.43% 97.19% 95.53% 106.43% 92.47% 76.04% 99.12%
Effective Tax Rate		 36.85% 37.19% 30.69% 23.17% 23.73% 22.72% 22.61% 30.96% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 58.62% 58.71% 99.78% 98.62% 78.24% 96.68% 107.62% 45.78% -24.15% -2.98% -216.49%
ROIC Less NNEP Spread (ROIC-NNEP)		 58.36% 58.14% 98.11% 96.08% 76.06% 96.39% 107.69% 44.89% -21.95% 6.47% -173.90%
Return on Net Nonoperating Assets (RNNOA)		 -32.69% -31.73% -64.12% -68.48% -58.70% -79.05% -93.48% -41.38% 16.93% -3.92% 116.06%
Return on Equity (ROE)		 25.93% 26.98% 35.66% 30.14% 19.53% 17.63% 14.14% 4.40% -7.22% -6.90% -100.44%
Cash Return on Invested Capital (CROIC)		 -2.50% 85.95% 91.06% 108.75% 104.41% 111.78% 165.98% 116.91% -174.44% 27.70% -95.86%
Operating Return on Assets (OROA)		 37.40% 37.21% 42.91% 32.67% 20.76% 18.58% 13.79% 4.03% -4.02% -0.48% -50.35%
Return on Assets (ROA)		 23.76% 23.46% 30.11% 26.09% 16.69% 13.95% 10.19% 2.96% -4.42% -3.94% -49.84%
Return on Common Equity (ROCE)		 25.93% 26.98% 35.66% 30.14% 19.53% 17.63% 14.14% 4.40% -7.22% -6.90% -100.42%
Return on Equity Simple (ROE_SIMPLE)		 24.72% 25.51% 32.22% 28.02% 19.88% 16.93% 15.16% 0.00% -7.72% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 20 24 36 35 24 24 19 4.18 -5.71 -1.07 -41
NOPAT Margin		 8.72% 9.45% 13.20% 12.52% 8.32% 7.77% 6.90% 1.69% -2.03% -0.47% -22.94%
Net Nonoperating Expense Percent (NNEP)		 0.25% 0.57% 1.68% 2.54% 2.18% 0.29% -0.07% 0.89% -2.20% -9.45% -42.60%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 3.80% - -1.26% -141.92%
Cost of Revenue to Revenue		 67.49% 68.17% 64.28% 66.37% 71.40% 72.23% 71.74% 69.10% 72.02% 69.54% 71.95%
SG&A Expenses to Revenue		 9.08% 9.15% 8.87% 8.74% 8.89% 9.79% 11.43% 16.85% 19.66% 17.03% 28.34%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 18.71% 16.79% 16.68% 17.34% 17.69% 17.72% 19.34% 28.46% 30.89% 31.13% 60.82%
Earnings before Interest and Taxes (EBIT)		 32 38 53 47 32 32 25 7.00 -6.78 -0.77 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 33 39 55 49 34 34 28 11 0.27 6.27 -48
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.16 3.33 5.70 2.78 3.73 4.37 3.96 2.98 1.05 1.02 1.69
Price to Tangible Book Value (P/TBV)		 3.20 3.36 5.74 2.80 3.76 4.39 3.99 3.15 1.89 1.92 2.69
Price to Revenue (P/Rev)		 1.12 1.25 2.41 1.32 1.71 2.03 1.80 1.33 0.36 0.38 0.27
Price to Earnings (P/E)		 12.79 13.04 17.69 9.91 18.77 25.79 26.12 63.84 0.00 0.00 0.00
Dividend Yield		 5.56% 5.02% 2.65% 5.86% 4.49% 3.68% 5.15% 7.71% 25.05% 0.00% 0.00%
Earnings Yield		 7.82% 7.67% 5.65% 10.09% 5.33% 3.88% 3.83% 1.57% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.95 7.27 15.39 8.01 14.54 22.08 30.54 38.11 1.11 1.05 3.64
Enterprise Value to Revenue (EV/Rev)		 0.96 1.01 2.12 0.97 1.34 1.64 1.39 0.91 0.16 0.14 0.15
Enterprise Value to EBITDA (EV/EBITDA)		 6.80 6.43 10.53 5.53 11.09 14.54 13.46 21.26 169.14 5.08 0.00
Enterprise Value to EBIT (EV/EBIT)		 6.96 6.66 10.95 5.79 11.87 15.64 14.92 32.03 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 11.03 10.69 16.10 7.71 16.15 21.11 20.10 53.64 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 10.71 5.33 15.56 6.06 9.82 12.43 20.42 8.06 10.66 6.75 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 7.31 17.64 7.00 12.10 18.26 13.03 21.00 0.00 3.20 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.56 -0.55 -0.65 -0.71 -0.77 -0.82 -0.87 -0.92 -0.77 -0.60 -0.67
Leverage Ratio		 1.09 1.15 1.18 1.16 1.17 1.26 1.39 1.49 1.63 1.75 2.02
Compound Leverage Factor		 1.10 1.15 1.20 1.20 1.23 1.23 1.33 1.58 1.51 1.33 2.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.03%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.97%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 28.09 14.64 25.93 16.16 15.96 11.93 8.70 6.33 3.10 3.08 0.45
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.55 4.46 5.81 6.79 5.30 3.59 2.68 2.27 1.30 1.26 0.84
Quick Ratio		 5.56 3.30 4.43 5.53 4.42 2.70 2.01 1.84 0.81 0.91 0.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.87 34 33 39 32 27 29 11 -41 9.95 -18
Operating Cash Flow to CapEx		 104.59% 445.15% 5,317.07% 7,280.32% 1,680.83% 1,647.82% 1,055.82% 528.57% 95.70% 92.27% -615.25%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 30.45 25.63 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 44.73 16.36 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 42.01 14.81 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 2.71 2.45 2.21 1.96 1.83 1.77 1.48 1.43 1.67 1.42 1.56
Accounts Receivable Turnover		 128.42 141.10 133.56 117.26 89.00 94.43 121.01 135.54 111.91 81.06 84.74
Inventory Turnover		 6.25 7.42 8.08 8.42 10.34 8.38 5.84 6.65 8.51 7.05 8.64
Fixed Asset Turnover		 20.86 9.75 9.30 10.14 10.81 11.93 10.91 9.78 10.64 8.18 6.49
Accounts Payable Turnover		 31.19 16.80 11.54 11.92 11.29 7.41 5.83 6.49 6.51 5.21 5.79
Days Sales Outstanding (DSO)		 2.84 2.59 2.73 3.11 4.10 3.87 3.02 2.69 3.26 4.50 4.31
Days Inventory Outstanding (DIO)		 58.37 49.22 45.18 43.37 35.31 43.53 62.48 54.92 42.90 51.76 42.24
Days Payable Outstanding (DPO)		 11.70 21.73 31.62 30.61 32.32 49.28 62.64 56.23 56.11 70.06 63.01
Cash Conversion Cycle (CCC)		 49.50 30.08 16.29 15.88 7.09 -1.88 2.85 1.38 -9.95 -13.80 -16.46
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 46 35 38 34 26 23 12 5.88 41 30 7.53
Invested Capital Turnover		 6.73 6.21 7.56 7.88 9.41 12.44 15.59 27.13 11.88 6.32 9.44
Increase / (Decrease) in Invested Capital		 21 -11 3.16 -3.64 -7.90 -3.69 -10 -6.49 36 -11 -23
Enterprise Value (EV)		 226 252 582 274 382 498 378 224 46 32 27
Market Capitalization		 263 310 660 374 485 617 489 328 101 87 49
Book Value per Share		 $4.09 $4.55 $5.62 $6.51 $6.45 $6.97 $5.88 $5.22 $4.57 $4.12 $1.35
Tangible Book Value per Share		 $4.05 $4.51 $5.58 $6.47 $6.40 $6.93 $5.84 $4.94 $2.53 $2.18 $0.85
Total Capital		 83 93 116 135 130 141 123 110 97 85 29
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -38 -59 -78 -101 -104 -119 -111 -104 -55 -55 -21
Capital Expenditures (CapEx)		 20 11 0.70 0.62 2.31 2.43 1.75 5.26 4.51 5.11 4.62
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 23 4.70 9.19 7.28 0.91 -2.47 -16 -31 -34 -39 -30
Debt-free Net Working Capital (DFNWC)		 61 63 87 108 105 116 95 73 21 16 -8.47
Net Working Capital (NWC)		 61 63 87 108 105 116 95 73 21 16 -8.47
Net Nonoperating Expense (NNE)		 -0.11 -0.28 -1.15 -2.26 -2.22 -0.32 0.08 -0.96 1.75 5.20 16
Net Nonoperating Obligations (NNO)		 -38 -59 -78 -101 -104 -119 -111 -104 -55 -55 -21
Total Depreciation and Amortization (D&A)		 0.77 1.37 2.13 2.23 2.26 2.43 2.74 3.55 7.06 7.04 9.39
Debt-free, Cash-free Net Working Capital to Revenue		 9.76% 1.89% 3.36% 2.57% 0.32% -0.81% -6.00% -12.59% -12.03% -17.01% -16.69%
Debt-free Net Working Capital to Revenue		 25.80% 25.46% 31.82% 38.04% 36.84% 38.29% 34.80% 29.45% 7.65% 7.09% -4.73%
Net Working Capital to Revenue		 25.80% 25.46% 31.82% 38.04% 36.84% 38.29% 34.80% 29.45% 7.65% 7.09% -4.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.02 $1.18 $1.83 $1.84 $1.29 $1.53 $1.05 $0.00 ($0.37) ($0.30) ($2.74)
Adjusted Weighted Average Basic Shares Outstanding		 20.12M 20.23M 20.35M 20.46M 20.04M 20.06M 20.18M 0.00 20.40M 20.60M 20.92M
Adjusted Diluted Earnings per Share		 $1.02 $1.17 $1.82 $1.84 $1.29 $1.52 $1.04 $0.00 ($0.37) ($0.30) ($2.74)
Adjusted Weighted Average Diluted Shares Outstanding		 20.25M 20.38M 20.43M 20.49M 20.06M 20.12M 20.36M 0.00 20.40M 20.60M 20.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.45M 20.53M 20.60M 20.22M 20.17M 20.27M 20.99M 0.00 20.61M 0.00 21.37M
Normalized Net Operating Profit after Tax (NOPAT)		 20 24 36 35 24 24 19 4.18 -5.71 -0.23 -22
Normalized NOPAT Margin		 8.72% 9.45% 13.20% 12.52% 8.32% 7.77% 6.90% 1.69% -2.03% -0.10% -12.28%
Pre Tax Income Margin		 13.88% 15.22% 19.65% 17.33% 11.93% 10.19% 8.88% 3.01% -2.23% -0.26% -32.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 35.54 22.38 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 26.33 16.62 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 32.83 20.83 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 23.62 15.07 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 71.40% 65.11% 46.86% 58.09% 84.34% 94.85% 130.28% 477.37% -166.63% -2.89% -0.04%
Augmented Payout Ratio		 71.40% 65.11% 46.86% 58.09% 128.82% 94.85% 130.28% 477.37% -166.63% -2.89% -0.04%

Quarterly Metrics And Ratios for PetMed Express

This table displays calculated financial ratios and metrics derived from PetMed Express' official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 21,169,327.00 21,147,006.00 - - - - 20,656,457.00 20,656,457.00 21,015,559.00 42,739,042.00 21,400,495.00
DEI Adjusted Shares Outstanding		 21,169,327.00 21,147,006.00 - - - - 20,656,457.00 20,656,457.00 21,015,559.00 42,739,042.00 21,400,495.00
DEI Earnings Per Adjusted Shares Outstanding		 0.03 -0.10 - - - - -0.56 -1.65 -0.41 -0.25 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.79% 10.95% 6.57% -13.15% -16.10% -18.88% -14.74% -22.70% -23.57% -21.75% -15.65%
EBITDA Growth		 -41.28% -334.57% -260.22% 11,217.86% -15.62% 230.17% -134.37% -599.56% -346.33% -701.98% 20.95%
EBIT Growth		 -71.65% -445.29% -25,171.43% 384.65% -34.46% 90.29% -66.92% -835.22% -1,206.08% -3,722.59% 7.51%
NOPAT Growth		 -81.91% -299.74% -2,755.66% 334.58% 185.02% 85.36% -56.98% -783.76% -521.08% -2,226.44% 5.45%
Net Income Growth		 -75.18% -856.13% -2,222.22% 430.46% 225.31% 65.12% -132.14% -1,009.75% -466.29% -1,392.65% 65.12%
EPS Growth		 -78.57% -900.00% -2,300.00% 400.00% 266.67% 70.00% -133.33% -1,016.67% -472.73% -1,566.67% 67.86%
Operating Cash Flow Growth		 38.92% -119.99% -26.73% -1,615.48% 1,050.97% 55.03% -1.59% -44.08% -129.42% -689.45% -167.66%
Free Cash Flow Firm Growth		 -20.90% -210.70% -680.17% 90.74% 181.29% 110.47% 117.80% 1,060.02% 699.22% 679.32% 177.68%
Invested Capital Growth		 12.74% 306.85% 604.68% 11.31% -5.37% -8.96% -26.60% -77.21% -83.65% -87.30% -75.25%
Revenue Q/Q Growth		 -9.26% -8.00% 1.82% 2.18% -12.34% -11.06% -2.31% 10.15% -13.32% -8.35% 5.31%
EBITDA Q/Q Growth		 4,975.00% -135.57% -59.74% 492.45% -62.16% -45.12% -387.61% -736.51% 81.34% -34.11% 62.23%
EBIT Q/Q Growth		 169.61% -346.32% -26.21% 231.54% -83.97% -136.49% -2,070.00% -479.37% 75.89% -26.10% 47.50%
NOPAT Q/Q Growth		 132.81% -540.25% -24.76% 230.17% -60.13% -122.61% -1,237.78% -466.98% 75.45% -24.93% 45.63%
Net Income Q/Q Growth		 162.94% -383.50% -147.46% 174.84% -38.04% -130.40% -1,546.96% -193.30% 75.05% -23.86% 61.52%
EPS Q/Q Growth		 150.00% -433.33% -140.00% 175.00% -38.89% -127.27% -1,766.67% -194.64% 75.15% -21.95% 64.00%
Operating Cash Flow Q/Q Growth		 -238.26% -233.72% 374.78% -219.54% 186.76% -115.78% 701.37% -275.00% 82.28% -323.41% 48.46%
Free Cash Flow Firm Q/Q Growth		 66.61% -738.07% 5.18% 96.51% 393.10% 7.92% 61.23% 88.24% 144.01% 5.23% -42.55%
Invested Capital Q/Q Growth		 9.83% 7.91% -18.15% 14.73% -6.63% 3.82% -34.00% -64.38% -33.01% -19.36% 28.64%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 28.26% 27.38% 27.33% 26.45% 29.06% 28.14% 29.94% 28.14% 27.98% 23.26% 32.56%
EBITDA Margin		 4.00% -1.55% -2.43% 9.33% 4.03% 2.48% -7.46% -61.86% -13.31% -19.48% -6.99%
Operating Margin		 1.23% -4.71% -5.77% 6.45% 0.93% -0.85% -11.86% -66.69% -18.89% -25.75% -13.29%
EBIT Margin		 1.59% -4.26% -5.28% 6.79% 1.24% -0.51% -11.54% -66.32% -18.45% -25.38% -12.66%
Profit (Net Income) Margin		 1.01% -3.10% -7.54% 5.52% 3.90% -1.33% -22.94% -66.73% -19.20% -25.95% -9.48%
Tax Burden Percent		 55.86% 76.64% 144.14% 79.67% 251.46% 292.15% 194.65% 100.03% 100.11% 100.10% 97.55%
Interest Burden Percent		 113.37% 95.11% 99.15% 102.06% 125.00% 89.63% 102.10% 100.58% 103.98% 102.14% 76.82%
Effective Tax Rate		 44.14% 0.00% 0.00% 20.33% -151.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 4.21% -28.94% -47.96% 30.86% 13.29% -3.04% -52.45% -339.01% -101.52% -129.77% -87.81%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.91% -29.10% -45.03% 30.37% 11.52% -2.25% -38.94% -315.34% -95.48% -121.39% -87.61%
Return on Net Nonoperating Assets (RNNOA)		 -2.46% 20.56% 34.72% -16.51% -6.18% 1.14% 23.56% 188.46% 60.13% 72.50% 58.47%
Return on Equity (ROE)		 1.75% -8.37% -13.23% 14.34% 7.11% -1.90% -28.89% -150.54% -41.39% -57.27% -29.34%
Cash Return on Invested Capital (CROIC)		 33.61% -131.16% -174.44% -13.26% 2.50% 9.64% 27.70% 29.71% 11.02% -4.12% -95.86%
Operating Return on Assets (OROA)		 2.59% -6.88% -8.79% 10.92% 2.09% -0.79% -16.45% -107.08% -29.70% -40.78% -19.71%
Return on Assets (ROA)		 1.64% -5.01% -12.57% 8.88% 6.56% -2.07% -32.69% -107.73% -30.91% -41.70% -14.77%
Return on Common Equity (ROCE)		 1.75% -8.37% -13.23% 14.34% 7.11% -1.90% -28.89% -150.52% -41.39% -57.26% -29.34%
Return on Equity Simple (ROE_SIMPLE)		 -0.85% -2.66% 0.00% -2.75% -1.00% 0.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.49 -2.15 -2.68 3.49 1.39 -0.32 -4.21 -24 -5.87 -7.33 -3.98
NOPAT Margin		 0.69% -3.29% -4.04% 5.14% 2.34% -0.59% -8.30% -46.68% -13.22% -18.02% -9.31%
Net Nonoperating Expense Percent (NNEP)		 0.30% 0.16% -2.93% 0.48% 1.77% -0.79% -13.51% -23.67% -6.04% -8.37% -0.20%
Return On Investment Capital (ROIC_SIMPLE)		 - -2.15% - - - -0.33% -4.95% -45.98% -13.53% -22.37% -13.77%
Cost of Revenue to Revenue		 71.74% 72.62% 72.67% 73.55% 70.94% 71.86% 70.06% 71.86% 72.02% 76.74% 67.44%
SG&A Expenses to Revenue		 16.85% 20.55% 21.27% 7.17% 17.61% 20.36% 24.62% 25.30% 31.95% 29.99% 26.66%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 27.02% 32.09% 33.10% 19.99% 28.13% 28.99% 41.80% 94.83% 46.87% 49.00% 45.86%
Earnings before Interest and Taxes (EBIT)		 1.13 -2.78 -3.51 4.62 0.74 -0.27 -5.86 -34 -8.19 -10 -5.42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.84 -1.01 -1.62 6.34 2.40 1.32 -3.79 -32 -5.91 -7.92 -2.99
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.16 1.60 1.05 0.89 0.79 1.04 1.02 1.33 1.20 2.09 1.69
Price to Tangible Book Value (P/TBV)		 3.84 2.83 1.89 1.64 1.40 1.83 1.92 1.75 1.66 3.18 2.69
Price to Revenue (P/Rev)		 0.80 0.58 0.36 0.31 0.29 0.40 0.38 0.32 0.26 0.37 0.27
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 278.98 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 11.71% 15.87% 25.05% 29.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.49 2.18 1.11 0.79 0.54 1.07 1.05 2.57 2.21 7.09 3.64
Enterprise Value to Revenue (EV/Rev)		 0.60 0.40 0.16 0.14 0.09 0.20 0.14 0.13 0.08 0.22 0.15
Enterprise Value to EBITDA (EV/EBITDA)		 37.70 38.15 169.14 5.72 3.89 5.87 5.08 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 31.39 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 8.10 0.00 0.00 0.00 0.00 405.42 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.27 15.97 10.66 0.00 6.98 10.25 6.75 28.92 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.99 0.00 0.00 0.00 20.84 10.63 3.20 3.21 5.64 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00
Financial Leverage		 -0.63 -0.71 -0.77 -0.54 -0.54 -0.51 -0.60 -0.60 -0.63 -0.60 -0.67
Leverage Ratio		 1.39 1.60 1.63 1.70 1.57 1.62 1.75 1.81 1.77 1.81 2.02
Compound Leverage Factor		 1.58 1.52 1.62 1.74 1.96 1.45 1.79 1.82 1.84 1.84 1.55
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.80% 0.67% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.80% 0.67% 0.00% 0.00%
Preferred Equity to Total Capital		 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% 0.03% 0.03%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.99% 99.19% 99.31% 99.97% 99.97%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.28 0.89 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.45 1.04 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01 0.00 0.00
Altman Z-Score		 4.62 3.63 3.16 3.57 3.65 3.85 2.97 2.14 2.62 2.61 2.58
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.38 1.32 1.30 1.33 1.45 1.43 1.26 1.18 1.05 0.89 0.84
Quick Ratio		 0.91 0.71 0.81 0.83 1.10 1.09 0.91 0.74 0.67 0.52 0.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.81 -40 -38 -1.33 3.91 4.22 6.81 13 31 33 19
Operating Cash Flow to CapEx		 -78.96% -230.90% 569.54% -1,247.00% 584.11% -150.06% 293.63% -949.77% -82.85% 0.00% -658.89%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.63 1.62 1.67 1.61 1.68 1.55 1.42 1.61 1.61 1.61 1.56
Accounts Receivable Turnover		 143.74 142.99 111.91 130.34 136.71 117.93 81.06 109.65 110.61 97.94 84.74
Inventory Turnover		 7.38 6.99 8.51 6.80 11.75 7.70 7.05 6.72 10.06 11.29 8.64
Fixed Asset Turnover		 10.37 10.64 10.64 10.16 9.75 8.94 8.18 7.71 7.27 6.68 6.49
Accounts Payable Turnover		 7.91 6.30 6.51 6.10 8.88 7.18 5.21 6.63 7.77 8.67 5.79
Days Sales Outstanding (DSO)		 2.54 2.55 3.26 2.80 2.67 3.10 4.50 3.33 3.30 3.73 4.31
Days Inventory Outstanding (DIO)		 49.45 52.22 42.90 53.67 31.06 47.37 51.76 54.31 36.29 32.33 42.24
Days Payable Outstanding (DPO)		 46.12 57.90 56.11 59.85 41.09 50.87 70.06 55.09 46.98 42.08 63.01
Cash Conversion Cycle (CCC)		 5.87 -3.12 -9.95 -3.38 -7.36 -0.40 -13.80 2.55 -7.39 -6.03 -16.46
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 47 51 41 48 44 46 30 11 7.26 5.85 7.53
Invested Capital Turnover		 6.11 8.78 11.88 6.00 5.68 5.11 6.32 7.26 7.68 7.20 9.44
Increase / (Decrease) in Invested Capital		 5.30 38 36 4.83 -2.52 -4.54 -11 -37 -37 -40 -23
Enterprise Value (EV)		 164 110 46 37 24 50 32 28 16 41 27
Market Capitalization		 217 160 101 83 76 100 87 69 52 68 49
Book Value per Share		 $4.74 $4.73 $4.57 $4.54 $4.68 $4.65 $4.12 $2.50 $2.08 $1.53 $1.35
Tangible Book Value per Share		 $2.67 $2.67 $2.53 $2.47 $2.63 $2.64 $2.18 $1.90 $1.51 $1.01 $0.85
Total Capital		 100 100 97 94 96 96 85 52 43 33 29
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.41 0.29 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.41 0.29 0.00 0.00
Net Debt		 -53 -49 -55 -46 -52 -50 -55 -41 -36 -27 -21
Capital Expenditures (CapEx)		 0.98 1.12 1.25 0.68 1.27 0.78 2.39 1.29 2.62 -0.02 0.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -26 -34 -27 -30 -30 -39 -31 -33 -33 -30
Debt-free Net Working Capital (DFNWC)		 23 23 21 19 22 20 16 10 2.77 -6.26 -8.47
Net Working Capital (NWC)		 23 23 21 19 22 20 16 10 2.77 -6.26 -8.47
Net Nonoperating Expense (NNE)		 -0.23 -0.12 2.33 -0.26 -0.93 0.39 7.43 10 2.65 3.22 0.08
Net Nonoperating Obligations (NNO)		 -53 -49 -55 -46 -52 -50 -55 -41 -36 -27 -21
Total Depreciation and Amortization (D&A)		 1.71 1.77 1.90 1.72 1.66 1.59 2.07 2.28 2.28 2.40 2.43
Debt-free, Cash-free Net Working Capital to Revenue		 -11.12% -9.49% -12.03% -9.85% -11.61% -12.01% -17.01% -14.56% -16.81% -17.75% -16.69%
Debt-free Net Working Capital to Revenue		 8.65% 8.36% 7.65% 7.14% 8.46% 8.27% 7.09% 4.85% 1.40% -3.35% -4.73%
Net Working Capital to Revenue		 8.65% 8.36% 7.65% 7.14% 8.46% 8.27% 7.09% 4.85% 1.40% -3.35% -4.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.10) ($0.25) $0.18 $0.11 ($0.03) ($0.56) ($1.65) ($0.41) ($0.50) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 20.43M 20.40M 20.51M 20.60M 20.63M 20.60M 20.76M 20.89M 21.01M 20.92M
Adjusted Diluted Earnings per Share		 $0.00 ($0.10) ($0.24) $0.18 $0.11 ($0.03) ($0.56) ($1.65) ($0.41) ($0.50) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 20.43M 20.40M 20.94M 20.94M 20.63M 20.60M 20.76M 20.89M 21.01M 20.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 20.61M 20.60M 20.66M 20.66M 0.00 0.00 21.37M 21.40M 21.37M
Normalized Net Operating Profit after Tax (NOPAT)		 0.49 -2.15 -2.68 3.49 0.39 -0.32 -3.37 -4.81 -5.87 -7.33 -3.98
Normalized NOPAT Margin		 0.69% -3.29% -4.04% 5.14% 0.65% -0.59% -6.65% -9.40% -13.22% -18.02% -9.31%
Pre Tax Income Margin		 1.80% -4.05% -5.23% 6.93% 1.55% -0.46% -11.78% -66.71% -19.18% -25.93% -9.72%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -2,901.65% -696.47% -166.63% -250.16% -21.60% 54.34% -2.89% -0.18% -0.05% -0.04% -0.04%
Augmented Payout Ratio		 -2,901.65% -696.47% -166.63% -250.16% -21.60% 54.34% -2.89% -0.18% -0.05% -0.04% -0.04%

Financials Breakdown Chart

Key Financial Trends

PetMed Express showed a mixed but clearly pressured trend over the past several quarters. Revenue has generally declined from the prior-year period, while profitability has deteriorated sharply, driven by heavy operating expenses and, in some periods, large impairment charges. The balance sheet still shows a sizable cash position and no obvious liquidity crisis, but cash has been falling and liabilities have remained elevated.

  • Strong cash position remains: PETS ended Q3 2026 with $26.9 million in cash and equivalents, giving it some near-term financial flexibility despite weak earnings.
  • Quarterly loss improved in Q4 2026: Net loss narrowed to $4.1 million from $10.6 million in Q3 2026, suggesting some operational improvement sequentially.
  • Operating losses improved quarter over quarter: Operating loss improved to $5.7 million in Q4 2026 from $10.5 million in Q3 2026.
  • Revenue stabilized sequentially in Q4 2026: Revenue rose to $42.8 million from $40.7 million in Q3 2026, a modest improvement.
  • Gross profit recovered in Q4 2026: Gross profit increased to $13.9 million from $9.5 million in the prior quarter, helped by a lower cost of revenue ratio.
  • No share dilution in the latest quarter: Basic and diluted shares were both 20.9 million in Q4 2026, which avoids adding pressure from dilution in that period.
  • Debt appears limited: Total noncurrent liabilities were relatively small compared with current liabilities, suggesting PETS is not burdened by heavy long-term debt.
  • Capital spending remains modest: Purchases of property and equipment were only $720,000 in Q4 2026, indicating limited near-term capex needs.
  • Profitability remains deeply negative: For Q4 2026, PETS posted a net loss of $4.1 million and an EPS of $(0.18), continuing a multi-quarter streak of losses.
  • Operating cash flow was negative: The company used $4.7 million of cash from operations in Q4 2026, which is a concern for long-term self-funding.
  • Full-year trend is weak versus 2025: Revenue fell from $50.8 million in Q4 2025 to $42.8 million in Q4 2026, while the prior year also included a much stronger cash flow profile.
  • Large impairment charges hit results in 2026: Q1 2026 included a $27.3 million impairment charge, and Q4 2025 also saw a $1.2 million impairment charge, showing asset write-down pressure.
  • Cash balance declined meaningfully over the year: Cash and equivalents fell from $45.0 million in Q1 2025 to $26.9 million in Q3 2026, reflecting ongoing cash burn.
  • Current liabilities are high relative to assets: At Q3 2026, current liabilities were $54.8 million versus current assets of $48.5 million, implying a short-term working capital strain.
  • Operating performance deteriorated sharply from early 2025: PETS moved from positive net income in Q1 and Q2 2025 to substantial losses in 2026, highlighting a significant reversal in business momentum.

Overall, PetMed Express appears to be in a turnaround phase, but the latest data still points to a challenged business. The good news is that the company has cash on hand and showed some sequential improvement in Q4 2026. The bad news is that losses, negative operating cash flow, and a weaker balance sheet trend remain the key issues investors will want to watch closely.

07/18/26 05:59 AM ETAI Generated. May Contain Errors.

PetMed Express Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PetMed Express' financial year ends in March. Their financial year 2026 ended on March 31, 2026.

PetMed Express' net income appears to be on a downward trend, with a most recent value of -$57.29 million in 2026, falling from $20.57 million in 2016. The previous period was -$6.27 million in 2025. Find out what analysts predict for PetMed Express in the coming months.

PetMed Express' total operating income in 2026 was -$58.67 million, based on the following breakdown:
  • Total Gross Profit: $50.22 million
  • Total Operating Expenses: $108.89 million

Over the last 10 years, PetMed Express' total revenue changed from $234.68 million in 2016 to $179.02 million in 2026, a change of -23.7%.

PetMed Express' total liabilities were at $52.25 million at the end of 2026, a 17.8% decrease from 2025, and a 637.6% increase since 2016.

In the past 10 years, PetMed Express' cash and equivalents has ranged from $21.41 million in 2026 to $118.72 million in 2021, and is currently $21.41 million as of their latest financial filing in 2026.

Over the last 10 years, PetMed Express' book value per share changed from 4.09 in 2016 to 1.35 in 2026, a change of -67.0%.


Related Companies

Financial statements for NASDAQ:PETS last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel